XML 34 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

Note 8 – Segment Information

 

The Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The measure of segment assets is reported on the balance sheet as total assets.

 

The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 

                 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2025   2024   2025   2024 
Research and development  $634,000   $1,307,000   $2,096,000   $3,868,000 
Salaries   373,000    340,000    1,006,000    1,106,000 
Insurance   54,000    42,000    175,000    194,000 
Stock-based compensation   379,000    —    386,000    222,000 
Operating expenses   1,942,000    1,915,000    3,164,000    5,211,000 
Other income   (268,000)   (193,000)   (1,504,000)   (1,214,000)
Net loss  $3,114,000   $3,411,000   $5,323,000   $9,387,000